{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:56:41Z","timestamp":1789419401744,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"DOI":"10.7759\/cureus.56008","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T09:44:08Z","timestamp":1710236648000},"source":"Crossref","is-referenced-by-count":3,"title":["A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery"],"prefix":"10.7759","author":[{"given":"Mihaela","family":"Andreescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Andreescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071810","article-title":"Aetiology of myeloproliferative neoplasms","volume":"12","author":"McMullin MF","year":"2020","unstructured":"McMullin MF, Anderson LA. Aetiology of myeloproliferative neoplasms. Cancers (Basel). 2020, 12:10.3390\/cancers12071810","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal R","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O, et al.. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014, 123:e123-33. 10.1182\/blood-2014-02-554634","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications","volume":"35","author":"Tremblay D","year":"2021","unstructured":"Tremblay D, Yacoub A, Hoffman R. Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications. Hematol Oncol Clin North Am. 2021, 35:159-76. 10.1016\/j.hoc.2020.12.001","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0400-3","article-title":"Risk factors for and management of MPN-associated bleeding and thrombosis","volume":"12","author":"Martin K","year":"2017","unstructured":"Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep. 2017, 12:389-96. 10.1007\/s11899-017-0400-3","journal-title":"Curr Hematol Malig Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon T","year":"2019","unstructured":"Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019, 19:184. 10.1186\/s12885-019-5387-9","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205989","article-title":"New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches","volume":"104","author":"Bar-Natan M","year":"2019","unstructured":"Bar-Natan M, Hoffman R. New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. Haematologica. 2019, 104:3-6. 10.3324\/haematol.2018.205989","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746479","article-title":"Elevated hematocrit enhances platelet accumulation following vascular injury","volume":"129","author":"Walton BL","year":"2017","unstructured":"Walton BL, Lehmann M, Skorczewski T, et al.. Elevated hematocrit enhances platelet accumulation following vascular injury. Blood. 2017, 129:2537-46. 10.1182\/blood-2016-10-746479","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy A","year":"2019","unstructured":"Guy A, Gourdou-Latyszenok V, Le Lay N, et al.. Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica. 2019, 104:70-81. 10.3324\/haematol.2018.195321","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1753483","article-title":"Thrombosis risk assessment in myeloproliferative neoplasm-is there a role for viscoelastic testing?","volume":"49","author":"Lim HY","year":"2023","unstructured":"Lim HY, Ho P. Thrombosis risk assessment in myeloproliferative neoplasm-is there a role for viscoelastic testing?. Semin Thromb Hemost. 2023, 49:173-81. 10.1055\/s-0042-1753483","journal-title":"Semin Thromb Hemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2021.100081","article-title":"Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective","volume":"5","author":"Kelliher S","year":"2021","unstructured":"Kelliher S, Falanga A. Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective. Thromb Upd. 2021, 5:100081. 10.1016\/j.tru.2021.100081","journal-title":"Thromb Upd"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000312","article-title":"Management of venous thromboembolism in myeloproliferative neoplasms","volume":"24","author":"Barbui T","year":"2017","unstructured":"Barbui T, De Stefano V. Management of venous thromboembolism in myeloproliferative neoplasms. Curr Opin Hematol. 2017, 24:108-14. 10.1097\/MOH.0000000000000312","journal-title":"Curr Opin Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111366","article-title":"Activated PRKCD-mediated neutrophil extracellular traps pathway may be the prothrombotic mechanism of neutrophils in polycythemia vera patients based on clinical retrospective analysis and bioinformatics study","volume":"127","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Chen K, Wang M, et al.. Activated PRKCD-mediated neutrophil extracellular traps pathway may be the prothrombotic mechanism of neutrophils in polycythemia vera patients based on clinical retrospective analysis and bioinformatics study. Int Immunopharmacol. 2024, 127:111366. 10.1016\/j.intimp.2023.111366","journal-title":"Int Immunopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz M","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, Landgren O, Derolf \u00c5R, Kristinsson SY, Andersson TM. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018, 168:317-25. 10.7326\/M17-0028","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101374","article-title":"Myeloproliferative neoplasms in adolescents and young adults","volume":"35","author":"Amerikanou R","year":"2022","unstructured":"Amerikanou R, Lambert J, Alimam S. Myeloproliferative neoplasms in adolescents and young adults. Best Pract Res Clin Haematol. 2022, 35:101374. 10.1016\/j.beha.2022.101374","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-018-1623-4","article-title":"Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms","volume":"45","author":"Ball S","year":"2018","unstructured":"Ball S, Thein KZ, Maiti A, Nugent K. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms. J Thromb Thrombolysis. 2018, 45:516-28. 10.1007\/s11239-018-1623-4","journal-title":"J Thromb Thrombolysis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007201","article-title":"Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs","volume":"6","author":"Sobas M","year":"2022","unstructured":"Sobas M, Kiladjian JJ, Beauverd Y, et al.. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022, 6:5171-83. 10.1182\/bloodadvances.2022007201","journal-title":"Blood Adv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0124-7","article-title":"The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia","volume":"7","author":"Yap YY","year":"2018","unstructured":"Yap YY, Law KB, Sathar J, et al.. The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. Exp Hematol Oncol. 2018, 7:31. 10.1186\/s40164-018-0124-7","journal-title":"Exp Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-019-02029-y","article-title":"Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms","volume":"49","author":"Seguro FS","year":"2020","unstructured":"Seguro FS, Teixeira LL, da Rosa LI, da Silva WF, Nardinelli L, Bendit I, Rocha V. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. J Thromb Thrombolysis. 2020, 49:667-72. 10.1007\/s11239-019-02029-y","journal-title":"J Thromb Thrombolysis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00829-w","article-title":"Pathophysiology of deep vein thrombosis","volume":"23","author":"Navarrete S","year":"2023","unstructured":"Navarrete S, Solar C, Tapia R, Pereira J, Fuentes E, Palomo I. Pathophysiology of deep vein thrombosis. Clin Exp Med. 2023, 23:645-54. 10.1007\/s10238-022-00829-w","journal-title":"Clin Exp Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008043","article-title":"Clinical insights into the origins of thrombosis in myeloproliferative neoplasms","volume":"137","author":"Moliterno AR","year":"2021","unstructured":"Moliterno AR, Ginzburg YZ, Hoffman R. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood. 2021, 137:1145-53. 10.1182\/blood.2020008043","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.06.023","article-title":"High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia","volume":"156","author":"Latagliata R","year":"2017","unstructured":"Latagliata R, Montanaro M, Cedrone M, et al.. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thromb Res. 2017, 156:168-71. 10.1016\/j.thromres.2017.06.023","journal-title":"Thromb Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio A","year":"2019","unstructured":"Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019, 3:1729-37. 10.1182\/bloodadvances.2019000211","journal-title":"Blood Adv"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner L","year":"2020","unstructured":"Ronner L, Podoltsev N, Gotlib J, et al.. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020, 135:1696-703. 10.1182\/blood.2019003347","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2018.09.003","article-title":"Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia","volume":"73","author":"Trifa AP","year":"2018","unstructured":"Trifa AP, B\u0103nescu C, Voina CM, et al.. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia. Blood Cells Mol Dis. 2018, 73:45-6. 10.1016\/j.bcmd.2018.09.003","journal-title":"Blood Cells Mol Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi E","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, et al.. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014, 123:1544-51. 10.1182\/blood-2013-11-539098","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: risk factors and development of a predictive model","volume":"9","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Zhou Y, Wang Y, et al.. Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: risk factors and development of a predictive model. Cancer Med. 2020, 9:2096-105. 10.1002\/cam4.2886","journal-title":"Cancer Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082100","article-title":"Clonal hematopoiesis and mutations of myeloproliferative neoplasms","volume":"12","author":"Kj\u00e6r L","year":"2020","unstructured":"Kj\u00e6r L. Clonal hematopoiesis and mutations of myeloproliferative neoplasms. Cancers (Basel). 2020, 12:10.3390\/cancers12082100","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-822824-1.00027-4","article-title":"Molecular testing in myeloproliferative neoplasms","author":"Furtado L","year":"2024","unstructured":"Furtado L, Brown N, Betz B. Molecular testing in myeloproliferative neoplasms. Diagnostic Molecular Pathology (Second Edition): A Guide to Applied Molecular Testing. Academic Press, Massachusetts, United States; 2024. 569-87. 10.1016\/B978-0-12-822824-1.00027-4"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.255117","article-title":"Acquired von Willebrand syndrome: focused for hematologists","volume":"105","author":"Franchini M","year":"2020","unstructured":"Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica. 2020, 105:2032-7. 10.3324\/haematol.2020.255117","journal-title":"Haematologica"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1515\/rjim-2015-0010","article-title":"Multiple Intestinal Lymphoma","volume":"53","author":"Mastalier B","year":"2015","unstructured":"Mastalier B, Deaconescu V, Elaiah W, et al.. Multiple Intestinal Lymphoma. Rom J Intern Med. 2015, 53:73-8. 10.1515\/rjim-2015-0010","journal-title":"Rom J Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071746","article-title":"Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding","volume":"12","author":"Awada H","year":"2020","unstructured":"Awada H, Voso MT, Guglielmelli P, Gurnari C. Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding. Cancers (Basel). 2020, 12:10.3390\/cancers12071746","journal-title":"Cancers (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2022218","article-title":"Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm","volume":"58","author":"Song IC","year":"2023","unstructured":"Song IC, Kang S, Lee MW, Ryu H, Lee HJ, Yun HJ, Jo DY. Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm. Blood Res. 2023, 58:42-50. 10.5045\/br.2023.2022218","journal-title":"Blood Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166408","article-title":"Screening for acquired von Willebrand syndrome in myelofibrosis-poor correlation with bleeding risk","volume":"140","author":"Melo R","year":"2022","unstructured":"Melo R, Rocha T, Kayano A, et al.. Screening for acquired von Willebrand syndrome in myelofibrosis-poor correlation with bleeding risk. Blood. 2022, 140:9713. 10.1182\/blood-2022-166408","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.924560","article-title":"Triple-negative essential thrombocythemia complicated by thrombosis and acquired von Willebrand disease in a young man","volume":"21","author":"Kanderi T","year":"2020","unstructured":"Kanderi T, Puthenpura M, Shrimanker I, Sapna F, Felter SC. Triple-negative essential thrombocythemia complicated by thrombosis and acquired von Willebrand disease in a young man. Am J Case Rep. 2020, 21:e924560. 10.12659\/AJCR.924560","journal-title":"Am J Case Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n A","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Guglielmelli P, et al.. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016, 101:926-31. 10.3324\/haematol.2016.146654","journal-title":"Haematologica"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi G","year":"2012","unstructured":"Finazzi G, Carobbio A, Thiele J, et al.. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012, 26:716-9. 10.1038\/leu.2011.258","journal-title":"Leukemia"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell PJ","year":"2012","unstructured":"Campbell PJ, MacLean C, Beer PA, et al.. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012, 120:1409-11. 10.1182\/blood-2012-04-424911","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie A","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, et al.. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016, 9:18. 10.1186\/s13045-016-0242-9","journal-title":"J Hematol Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S375777","article-title":"Surgical complications in myeloproliferative neoplasm patient with essential thrombocythemia: a case report","volume":"15","author":"Rinaldi I","year":"2022","unstructured":"Rinaldi I, Muthalib A, Wijayadi T, et al.. Surgical complications in myeloproliferative neoplasm patient with essential thrombocythemia: a case report. Int Med Case Rep J. 2022, 15:491-7. 10.2147\/IMCRJ.S375777","journal-title":"Int Med Case Rep J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.4103\/0970-9185.130102","article-title":"Incidental thrombocytosis: Should it concern the anesthesiologist?","volume":"30","author":"Kiro K","year":"2014","unstructured":"Kiro K, Ganjoo P, Saigal D, Hansda U. Incidental thrombocytosis: Should it concern the anesthesiologist?. J Anaesthesiol Clin Pharmacol. 2014, 30:281-3. 10.4103\/0970-9185.130102","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23599","article-title":"TEG and ROTEM: technology and clinical applications","volume":"89","author":"Whiting D","year":"2014","unstructured":"Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol. 2014, 89:228-32. 10.1002\/ajh.23599","journal-title":"Am J Hematol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2020.1742309","article-title":"Use of rotational thromboelastometry for a global screening of coagulation profile in patients of myeloproliferative neoplasms","volume":"32","author":"\u015eahin DG","year":"2021","unstructured":"\u015eahin DG, Akay OM, Uskudar Teke H, And\u0131c N, Gunduz E. Use of rotational thromboelastometry for a global screening of coagulation profile in patients of myeloproliferative neoplasms. Platelets. 2021, 32:280-3. 10.1080\/09537104.2020.1742309","journal-title":"Platelets"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(16)30159-1","article-title":"PO-26-Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN)","volume":"140","author":"Giaccherini C","year":"2016","unstructured":"Giaccherini C, Verzeroli C, Marchetti M, et al.. PO-26-Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). Thromb Res. 2016, 140:185-6. 10.1016\/S0049-3848(16)30159-1","journal-title":"Thromb Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221117482","article-title":"Thrombosis in myeloproliferative neoplasms: a single center experience of using whole blood platelet aggregation studies for risk assessment and thromboprophylaxis","volume":"28","author":"Manoharan A","year":"2022","unstructured":"Manoharan A, Gemmell R, Cavanaugh L, Shadood N. Thrombosis in myeloproliferative neoplasms: a single center experience of using whole blood platelet aggregation studies for risk assessment and thromboprophylaxis. Clin Appl Thromb Hemost. 2022, 28:10.1177\/10760296221117482","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider M","year":"2016","unstructured":"Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016, 91:390-4. 10.1002\/ajh.24293","journal-title":"Am J Hematol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"Guglielmelli P","year":"2020","unstructured":"Guglielmelli P, Carobbio A, Rumi E, et al.. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J. 2020, 10:21. 10.1038\/s41408-020-0289-2","journal-title":"Blood Cancer J"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.016","article-title":"Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk predicts post-Transplant outcomes","volume":"24","author":"Samuelson Bannow BT","year":"2018","unstructured":"Samuelson Bannow BT, Salit RB, Storer BE, et al.. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk predicts post-Transplant outcomes. Biol Blood Marrow Transplant. 2018, 24:386-92. 10.1016\/j.bbmt.2017.09.016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison CN","year":"2010","unstructured":"Harrison CN, Bareford D, Butt N, et al.. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010, 149:352-75. 10.1111\/j.1365-2141.2010.08122.x","journal-title":"Br J Haematol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.5368","article-title":"A latent form of essential thrombocythemia presenting as portal cavernoma","volume":"15","author":"Cai XY","year":"2009","unstructured":"Cai XY, Zhou W, Hong DF, Cai XJ. A latent form of essential thrombocythemia presenting as portal cavernoma. World J Gastroenterol. 2009, 15:5368-70. 10.3748\/wjg.15.5368","journal-title":"World J Gastroenterol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2013.07.001","article-title":"Budd-Chiari syndrome following laparoscopic cholecystectomy","volume":"3","author":"Amarapurkar PD","year":"2013","unstructured":"Amarapurkar PD, Parekh SJ, Sundeep P, Amarapurkar DN. Budd-Chiari syndrome following laparoscopic cholecystectomy. J Clin Exp Hepatol. 2013, 3:256-9. 10.1016\/j.jceh.2013.07.001","journal-title":"J Clin Exp Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi R","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004, 350:114-24. 10.1056\/NEJMoa035572","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04963-z","article-title":"Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera","volume":"101","author":"Triguero A","year":"2022","unstructured":"Triguero A, Pedraza A, P\u00e9rez-Encinas M, et al.. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Ann Hematol. 2022, 101:2231-9. 10.1007\/s00277-022-04963-z","journal-title":"Ann Hematol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi A","year":"2020","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020, 95:1599-613. 10.1002\/ajh.26008","journal-title":"Am J Hematol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian JJ","year":"2020","unstructured":"Kiladjian JJ, Zachee P, Hino M, et al.. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020, 7:e226-37. 10.1016\/S2352-3026(19)30207-8","journal-title":"Lancet Haematol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0380","article-title":"Where to turn for second-line cytoreduction after hydroxyurea in polycythemia vera?","volume":"21","author":"Nazha A","year":"2016","unstructured":"Nazha A, Gerds AT. Where to turn for second-line cytoreduction after hydroxyurea in polycythemia vera?. Oncologist. 2016, 21:475-80. 10.1634\/theoncologist.2015-0380","journal-title":"Oncologist"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0042-7","article-title":"Polycythemia vera treatment algorithm 2018","volume":"8","author":"Tefferi A","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018, 8:3. 10.1038\/s41408-017-0042-7","journal-title":"Blood Cancer J"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0142-z","article-title":"Prefibrotic myelofibrosis: treatment algorithm 2018","volume":"8","author":"Finazzi G","year":"2018","unstructured":"Finazzi G, Vannucchi AM, Barbui T. Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer J. 2018, 8:104. 10.1038\/s41408-018-0142-z","journal-title":"Blood Cancer J"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi A","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021, 96:145-62. 10.1002\/ajh.26050","journal-title":"Am J Hematol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2621-2","article-title":"Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)","volume":"95","author":"Appelmann I","year":"2016","unstructured":"Appelmann I, Kreher S, Parmentier S, et al.. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol. 2016, 95:707-18. 10.1007\/s00277-016-2621-2","journal-title":"Ann Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/229780-a-review-about-the-assessment-of-the-bleeding-and-thrombosis-risk-for-patients-with-myeloproliferative-neoplasms-scheduled-for-surgery","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T09:44:14Z","timestamp":1710236654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/229780-a-review-about-the-assessment-of-the-bleeding-and-thrombosis-risk-for-patients-with-myeloproliferative-neoplasms-scheduled-for-surgery"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.56008","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}